Meanwhile, noting differences between children and adult AML surface protein expression, Willier et al. identified CD33/CLL-1 as the preferred combination for pediatric AML, although they cautioned that this approach may require a safety switch or subsequent HSCT [143]. This evidence concerns the gene CLEC12A and acute myeloid leukemia.